Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis and Infinity announce small molecule collaboration
Under the agreement, Novartis has made a significant equity investment in Infinity and will pay additional fees expected to exceed $10 million over the course of the two
Under the agreement, Novartis has made a significant equity investment in Infinity and will pay additional fees expected to exceed $10 million over the course of the two
PolyMedix plans to file an investigational new drug (IND) application and to initiate human clinical trials of the compound later this year. In addition, the company plans to
Under the terms of the agreement, TaiGen will be responsible for conducting phase Ib and phase II development of the compound to meet worldwide regulatory standards. If phase
Statins reduce this buildup by reducing C-reactive protein, a measure of inflammation in the arteries. A related analysis at Boston’s Brigham and Women’s Hospital demonstrates that lowering C-reactive
The randomized, placebo controlled, double blind phase IIb study is designed to evaluate the effectiveness of CS-917 in lowering blood glucose levels in patients with type 2 diabetes.
In addition, Diatos has also received rights to sublicense OncoGel and to develop and commercialize second generation OncoGel products. Diatos and MacroMed, both privately held biopharmaceutical companies, will
The researchers demonstrated that ceftriaxone, a beta-lactam antibiotic, turns on a gene that encodes for the glutamate transporter GLT-1. As a result, more glutamate transporter protein is present
Epratuzumab is a versatile humanized monoclonal antibody targeting B-cell-mediated autoimmune diseases and non-Hodgkin’s Lymphoma. According to Cynthia Sullivan, president and CEO of Immunomedics, the company’s clinical plans for
Upon consummation of the transaction, Tarpan shareholders will own approximately 20% of the shares of Manhattan on a fully-diluted basis. Upon the close of the transaction, Manhattan Pharmaceuticals’
Zelapar (selegiline hydrochloride) is a late-stage candidate under review by the FDA as an oral tablet using the patented Zydis fast-dissolving technology and is being developed as an